Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

Détails

ID Serval
serval:BIB_1AD2156B1668
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Périodique
Blood
Auteur(s)
Ghielmini  M., Schmitz  S. F., Cogliatti  S. B., Pichert  G., Hummerjohann  J., Waltzer  U., Fey  M. F., Betticher  D. C., Martinelli  G., Peccatori  F., Hess  U., Zucca  E., Stupp  R., Kovacsovics  T., Helg  C., Lohri  A., Bargetzi  M., Vorobiof  D., Cerny  T.
ISSN
0006-4971 (Print)
Statut éditorial
Publié
Date de publication
06/2004
Volume
103
Numéro
12
Pages
4416-23
Notes
Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jun 15
Résumé
The potential benefits of extended rituximab treatment have been investigated in a randomized trial comparing the standard schedule with prolonged treatment in 202 patients with newly diagnosed or refractory/relapsed follicular lymphoma (FL). All patients received standard treatment (rituximab 375 mg/m(2) weekly x 4). In 185 evaluable patients, the overall response rate was 67% in chemotherapy-naive patients and 46% in pretreated cases (P <.01). Patients responding or with stable disease at week 12 (n = 151) were randomized to no further treatment or prolonged rituximab administration (375 mg/m(2) every 2 months for 4 times). At a median follow-up of 35 months, the median event-free survival (EFS) was 12 months in the no further treatment versus 23 months in the prolonged treatment arm (P =.02), the difference being particularly notable in chemotherapy-naive patients (19 vs 36 months; P =.009) and in patients responding to induction treatment (16 vs 36 months; P =.004). The number of t(14;18)-positive cells in peripheral blood (P =.0035) and in bone marrow (P =.0052) at baseline was predictive for clinical response. Circulating normal B lymphocytes and immunoglobulin M (IgM) plasma levels decreased for a significantly longer time after prolonged treatment, but the incidence of adverse events was not increased. In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly improves the EFS.
Mots-clé
Adult Aged Aged, 80 and over Antibodies, Monoclonal/administration & dosage/*therapeutic use/toxicity Antineoplastic Agents/administration & dosage/*therapeutic use/toxicity DNA Primers Disease-Free Survival Drug Administration Schedule Humans Lymphoma, Follicular/*drug therapy/genetics/pathology/physiopathology Middle Aged Neoplasm Staging Polymerase Chain Reaction Time Factors
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
03/03/2018 14:29
Données d'usage